As of 2025-10-27, the Relative Valuation of Eiger BioPharmaceuticals Inc (EIGR) is - USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.50 USD, the upside of Eiger BioPharmaceuticals Inc based on Relative Valuation is -.
The range of the Relative Valuation is - USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | P/E |